HSA
CORT icon

Hussman Strategic Advisors’s Corcept Therapeutics CORT Stock Holding History

Hussman Strategic Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-126,000
Closed -$5.08M – 250
2026
Q1 		$5.08M Buy
126,000
+94,500
+300% +$3.53M 1.1% 1
2025
Q4 		$1.1M Hold
31,500
– – 0.27% 170
2025
Q3 		$2.62M Sell
31,500
-10,500
-25% -$760K 0.57% 54
2025
Q2 		$3.08M Hold
42,000
– – 0.7% 44
2025
Q1 		$4.8M Hold
42,000
– – 1.16% 8
2024
Q4 		$2.12M Hold
42,000
– – 0.63% 56
2024
Q3 		$1.94M Sell
42,000
-63,000
-60% -$2.24M 0.48% 94
2024
Q2 		$3.41M Buy
105,000
+21,000
+25% +$575K 0.94% 17
2024
Q1 		$2.12M Buy
84,000
+31,500
+60% +$744K 0.49% 80
2023
Q4 		$1.71M Sell
52,500
-10,500
-17% -$288K 0.39% 101
2023
Q3 		$1.72M Sell
63,000
-30,600
-33% -$886K 0.33% 126
2023
Q2 		$2.08M Sell
93,600
-18,000
-16% -$414K 0.38% 113
2023
Q1 		$2.42M Buy
111,600
+18,600
+20% +$408K 0.38% 110
2022
Q4 		$1.89M Sell
93,000
-31,000
-25% -$777K 0.31% 131
2022
Q3 		$3.18M Sell
124,000
-15,500
-11% -$415K 0.55% 52
2022
Q2 		$3.32M Buy
139,500
+87,500
+168% +$1.91M 0.57% 44
2022
Q1 		$1.17M Hold
52,000
– – 0.23% 155
2021
Q4 		$1.03M Sell
52,000
-103,000
-66% -$2.09M 0.23% 148
2021
Q3 		$3.05M Buy
155,000
+62,000
+67% +$1.3M 0.67% 28
2021
Q2 		$2.05M Buy
93,000
+21,000
+29% +$467K 0.42% 82
2021
Q1 		$1.71M Sell
72,000
-71,500
-50% -$1.91M 0.35% 102
2020
Q4 		$3.75M Sell
143,500
-111,500
-44% -$2.35M 0.98% 4
2020
Q3 		$4.44M Buy
255,000
+75,000
+42% +$1.2M 1.17% 7
2020
Q2 		$3.03M Buy
180,000
+26,000
+17% +$365K 0.77% 13
2020
Q1 		$1.83M Buy
154,000
+51,500
+50% +$637K 0.49% 72
2019
Q4 		$1.24M Buy
102,500
+41,204
+67% +$574K 0.39% 99
2019
Q3 		$866K Buy
+61,296
New +$753K 0.25% 139
2018
Q3 		– Sell
-125,000
Closed -$1.97M – 226
2018
Q2 		$1.97M Buy
+125,000
New +$2.17M 0.53% 86

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's CORT Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 126,000 shares — an estimated $5.08M sold.

Hussman Strategic Advisors first reported a position in CORT in Q2 2018 and held it in 28 quarters. The position peaked at $5.08M in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 126,000 Corcept Therapeutics shares in Q2 2026, an estimated $5.08M.
  • Hussman Strategic Advisors first reported a position in Corcept Therapeutics in Q2 2018 and held it in 28 quarters.
  • Hussman Strategic Advisors's Corcept Therapeutics position peaked at $5.08M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.